ACP
MAZE

Acuta Capital Partners’s Maze Therapeutics MAZE Stock Holding History

Acuta Capital Partners’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$577K Sell
19,335
-665
-3% -$29.3K 0.41% 26
2025
Q4 		$829K Buy
+20,000
New +$687K 0.56% 22

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acuta Capital Partners's MAZE Position: Q1 2026 in Review

Acuta Capital Partners reduced its Maze Therapeutics (MAZE) stake by 3.3% in Q1 2026, selling an estimated $29.3K and leaving 19,335 shares worth $577K. The position accounts for 0.41% of the portfolio, ranked #26.

Acuta Capital Partners first reported a position in MAZE in Q4 2025 and has held it in 2 quarters since. The position peaked at $829K in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Acuta Capital Partners held 19,335 shares of Maze Therapeutics worth $577K as of Q1 2026.
  • Acuta Capital Partners sold 665 Maze Therapeutics shares in Q1 2026, an estimated $29.3K.
  • Maze Therapeutics made up 0.41% of Acuta Capital Partners's portfolio in Q1 2026, its #26 holding.
  • Acuta Capital Partners first reported a position in Maze Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Acuta Capital Partners's Maze Therapeutics position peaked at $829K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.